Document Detail


A single-pill combination of amlodipine besylate and atorvastatin calcium.
MedLine Citation:
PMID:  16628258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This review describes the clinical profile and rationale for the development of a single-pill formulation of the calcium channel blocker amlodipine besylate, a blood pressure-lowering agent with pleiotropic effects, and atorvastatin calcium, a statin with lipid-lowering as well as pleiotropic anti-atherosclerotic properties. Amlodipine and atorvastatin have been demonstrated in numerous clinical trials to be highly effective in lowering blood pressure and low-density lipoprotein cholesterol (LDL-C). Furthermore, both amlodipine and atorvastatin have been demonstrated to reduce cardiovascular events in a broad range of patients. The amlodipine/atorvastatin single pill has been shown to improve patients' achievement of national guideline-recommended blood pressure and lipid target levels and exhibits a safety profile consistent with its parent compounds. The combination pill is available in formulations appropriate for administration across therapeutic dose ranges targeted to a wide variety of hypertensive patients with additional risk factors and differing degrees of cardiovascular risk, or with manifest cardiovascular disease. Single-pill amlodipine/atorvastatin has the potential to improve the management of hypertensive patients with additional cardiovascular risk factors, especially dyslipidemia, by reducing pill burden and prescription costs. This potential has important implications because hypertensive patients with additional risk factors represent a large proportion of those at risk for cardiovascular events.
Authors:
Roy Blank
Related Documents :
6487508 - Cardiovascular and biochemical responses to nebulised salbutamol in normal subjects.
20100998 - Individual/neighborhood social factors and blood pressure in the record cohort study: w...
17617758 - The impact of plasma high-sensitivity c-reactive protein levels on cardiovascular risk ...
48728 - High blood-pressure: a risk factor for cancer mortality?
8972888 - Body mass index is associated with differential seasonal change in ambulatory blood pre...
20726848 - Detecting activation of the sympatho-adrenal axis from haemodynamic recordings, in cons...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  42     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-04-21     Completed Date:  2006-08-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  157-75     Citation Subset:  IM    
Copyright Information:
Copyright 2006 Prous Science.
Affiliation:
Southern Piedmont Primary Care, Presbyterian Hospital, Charlotte, North Carolina 28112, USA. rcblank@novanthealth.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / adverse effects,  pharmacokinetics,  therapeutic use*
Anticholesteremic Agents / adverse effects,  pharmacokinetics,  therapeutic use
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use
Calcium Channel Blockers / adverse effects,  pharmacokinetics,  therapeutic use
Clinical Trials as Topic
Drug Combinations
Dyslipidemias / drug therapy*,  metabolism
Heptanoic Acids / adverse effects,  pharmacokinetics,  therapeutic use*
Humans
Hypertension / drug therapy*,  metabolism
Pyrroles / adverse effects,  pharmacokinetics,  therapeutic use*
Tablets
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Drug Combinations; 0/Heptanoic Acids; 0/Pyrroles; 0/Tablets; 110862-48-1/atorvastatin; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical experience with erlotinib in non-small-cell lung cancer.
Next Document:  Ranolazine: focusing on angina pectoris.